Observational to Investigate the Efficacy of CRESTOR 5mg in Reaching LDL-C Target Goals in Patients Who Are at High Risk for a Cardiovascular Event

NCT00347217 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3840

Last updated 2011-08-30

No results posted yet for this study

Summary

Observational study to investigate the use and efficacy of CRESTOR 5 mg in reaching LDL-C target goals in both statin naïve and statin treated primary and secondary prevention patients at high risk for a cardiovascular event.

Conditions

  • Hypercholesteremia

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Netherlands Medical Director, MD · AstraZeneca

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Completion
2009-01-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00347217 on ClinicalTrials.gov